

IMMUNOBIOLOGICS

IMMUNOBIOLOGIC	PRIMARY IMMUNIZATION SCHEDULE	BOOSTER SCHEDULE	COMMENTS AND CONTRAINDICATIONS
<p>Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed and Inactivated Poliovirus Vaccine (DTaP-IPV)</p> <p>KINRIX™ GlaxoSmithKline Biologicals</p>	<p>This vaccine is not approved for the primary series of DTaP and/or IPV</p>	<p>Children 4 through 6 years</p> <p>Fifth dose: 0.5 mL IM at least 6 months after the fourth dose of DTaP and 4 weeks after the third dose of IPV</p> <p>See comments</p> <p>DTaP: A fifth dose of DTaP – containing vaccine is not needed if the fourth DTaP dose was given on or after the fourth birthday.</p> <p>IPV: A fourth dose of IPV – containing vaccine is not needed if the third IPV dose was given on or after the fourth birthday.</p> <p>In addition, if four IPV doses are administered after 6 weeks of age and are all separated by at least 4 weeks, another dose is not needed, even if the fourth dose was administered before 4 years of age.</p>	<p>A single dose of combined DTaP-IPV vaccine (KINRIX) is indicated for active immunization against diphtheria, tetanus, pertussis, and poliomyelitis as the fifth dose in the diphtheria, tetanus, and acellular pertussis (DTaP) vaccine series and the fourth dose in the inactivated poliovirus vaccine (IPV) series in children 4 through 6 years of age whose previous DTaP vaccine doses have been with INFANRIX® (DTaP) and/or PEDIARIX® (DTaP-Hep B-IPV) for the first three doses and INFANRIX for the fourth dose. Although it is recommended that whenever possible the same brand of DTaP vaccine be used for all doses of the vaccination series, vaccination should not be deferred because the brand of DTaP used earlier is not known or is not in stock. In this the case the combined DTaP-IPV vaccine may be used for the fifth dose of the DTaP vaccine series.</p> <p>The combined DTaP-IPV vaccine may be used when any component of the combination is indicated, and if the other components are not contraindicated for the booster dose at age 4-6 years.</p> <p>Adverse Reactions: The adverse reactions are expected to be the same as those of the individual component vaccines. See component vaccines for possible adverse reactions. Note that in clinical trials DTaP-IPV combined vaccine caused a small but statistically significant increase in injection-site pain compared to separately administered DTaP and IPV vaccines.</p> <p>Precautions: The precautions are the same as they are for the individual component vaccines.</p> <p>Contraindications: The contraindications are the same as they are for the individual component vaccines.</p>